Moderna (MRNA) Long-Term Deferred Tax (2021 - 2024)

Moderna (MRNA) has 4 years of Long-Term Deferred Tax data on file, last reported at $81.0 million in Q3 2024.

• On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $81.0 million in Q3 2024; TTM through Sep 2024 was $81.0 million, a N/A change from a year earlier, with the FY2023 full-year figure at $81.0 million, down 91.75% from the prior year.
• Long-Term Deferred Tax for Q3 2024 stood at $81.0 million, roughly flat from $81.0 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for MRNA reached as high as $1.5 billion in Q2 2023 and fell as low as $50.0 million in Q1 2021.
• Historically, Long-Term Deferred Tax has averaged $485.5 million across 4 years, with a median of $203.5 million in 2021.
• Across the five-year window, Long-Term Deferred Tax surged 1089.39% in 2022 and tumbled 94.53% in 2024, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $326.0 million in 2021, then jumped by 201.23% to $982.0 million in 2022, then slumped by 91.75% to $81.0 million in 2023, then changed by 0.0% to $81.0 million in 2024.
• Per Business Quant data, the three most recent Long-Term Deferred Tax figures were $81.0 million in Q3 2024, $81.0 million in Q2 2024, and $81.0 million in Q1 2024.